Deciphera Pharmaceuticals Shares Outstanding 2016-2021 | DCPH

Deciphera Pharmaceuticals shares outstanding from 2016 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Deciphera Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2020 56
2019 43
2018 35
2017 17
2016 12
2015 4
Deciphera Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 58
2021-03-31 58
2020-12-31 56
2020-09-30 56
2020-06-30 56
2020-03-31 54
2019-12-31 43
2019-09-30 44
2019-06-30 38
2019-03-31 38
2018-12-31 35
2018-09-30 38
2018-06-30 34
2018-03-31 33
2017-12-31 32
2017-09-30 12
2017-06-30 12
2017-03-31 12
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.969B $0.042B
Deciphera Pharmaceuticals, LLC is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib which are in clinical stage. Deciphera Pharmaceuticals, LLC is based in WALTHAM, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29